



Revista de la Facultad de Medicina

ISSN: 2357-3848

ISSN: 0120-0011

Universidad Nacional de Colombia

Paz-Meneses, Manuel Agustín; Mora-Pabón, Guillermo
Use of the ROSE risk score for predicting mortality and
cardiovascular events in adult patients at 7 and 30 days of syncope
Revista de la Facultad de Medicina, vol. 64, no. 3, 2016, July-September, pp. 471-475
Universidad Nacional de Colombia

DOI: 10.15446/revfacmed.v64n3.53015

Available in: <http://www.redalyc.org/articulo.oa?id=576364352012>

- How to cite
- Complete issue
- More information about this article
- Journal's webpage in redalyc.org

UNEM [redalyc.org](http://www.redalyc.org)

Scientific Information System Redalyc

Network of Scientific Journals from Latin America and the Caribbean, Spain and
Portugal

Project academic non-profit, developed under the open access initiative

ORIGINAL RESEARCH

DOI: <http://dx.doi.org/10.15446/revfacmed.v64n3.53015>

Use of the ROSE risk score for predicting mortality and cardiovascular events in adult patients at 7 and 30 days of syncope

Aplicación del puntaje de riesgo de la escala ROSE para predicción de mortalidad y desenlaces cardiovasculares mayores en pacientes adultos con síncope a 7 y 30 días

Received: 11/09/2015. Accepted: 23/11/2015.

Manuel Agustín Paz-Meneses¹ • Guillermo Mora-Pabón^{1,2}¹ Universidad Nacional de Colombia - Bogotá Campus - Faculty of Medicine - Department of Internal Medicine - Bogotá, D.C. - Colombia.² Fundación Santa Fe de Bogotá - Internal Medicine - Bogotá - Colombia.

Corresponding author: Guillermo Mora-Pabón. Department of Internal Medicine, Faculty of Medicine, Universidad Nacional de Colombia. Carrera 30 No. 45-03, building 471, office 510. Phone number: +57 1 3165000. Bogotá, D.C. Colombia. Email: gmorap@unal.edu.co.

| Abstract |

Introduction: The use of the ROSE risk score after syncope provides the possibility of identifying patients at risk of death or other important adverse events after 30 days of admission to the emergency department.

Objective: To evaluate the performance of ROSE score in terms of mortality prediction and major adverse events at 7 and 30 days in adult patients with syncope admitted to the emergency department.

Materials and methods: A prospective cohort study in patients with syncope who were admitted to the emergency room was performed. An operational analysis of the predictive ability for detection of possible complications was done by calculating sensitivity, specificity, positive and negative predictive values and ROC curves.

Results: 60 patients were evaluated. An area under the curve for prediction of mortality or major outcome at 7 and 30 days of 0.62 (95%CI: 0.45-0.78) was obtained, with sensitivity of 60%, specificity of 18.18%, PPV of 6.25% and NPV of 83%.

Conclusion: ROSE score showed low sensitivity for predicting mortality or serious outcomes at 7 and 30 days. Its high negative predictive value makes it a useful prognostic tool in low risk patients.

Keywords: Syncope; Cardiovascular; Prognosis (MeSH).

Paz-Meneses MA, Mora-Pabón G. Use of the ROSE risk score for predicting mortality and cardiovascular events in adult patients at 7 and 30 days of syncope. Rev. Fac. Med. 2016;64(3):471-5. English. doi: <http://dx.doi.org/10.15446/revfacmed.v64n3.53015>.

| Resumen |

Introducción. El puntaje de riesgo ROSE para síncope tiene la capacidad de identificar pacientes en riesgo de presentar mortalidad

o cualquier otro desenlace adverso mayor a los 30 días de su ingreso a urgencias.

Objetivo. Evaluar el rendimiento pronóstico del puntaje para predicción de mortalidad o desenlaces adversos mayores a 7 y 30 días en pacientes adultos con síncope en el servicio de urgencias.

Materiales y métodos. Estudio de cohorte prospectivo en pacientes con síncope admitidos en urgencias. Se realizó un análisis operativo de la capacidad predictiva de detección de riesgo de complicaciones calculando sensibilidad, especificidad, valor predictivo positivo (VPP) y negativo (VPN) y curvas ROC.

Resultados. Se evaluaron 60 pacientes en los que se obtuvo un área bajo la curva para predicción de mortalidad o desenlaces mayores, tanto a los 7 como a los 30 días, de 0.62 (IC95%: 0.45-0.78), con sensibilidad de 60%, especificidad de 18.18%, VPP de 6.25% y VPN de 83%.

Conclusión. El puntaje ROSE mostró una sensibilidad baja para predicción de mortalidad o desenlaces serios mayores a 7 y 30 días. Su alto valor predictivo negativo la hace una herramienta de pronóstico con utilidad en los pacientes de bajo riesgo.

Palabras clave: Síncope; Cardiovascular; Pronóstico (DeCS).

Paz-Meneses MA, Mora-Pabón G. [Aplicación del puntaje de riesgo de la escala ROSE para predicción de mortalidad y desenlaces cardiovasculares mayores en pacientes adultos con síncope a 7 y 30 días]. Rev. Fac. Med. 2016;64(3):471-5. English. doi: <http://dx.doi.org/10.15446/revfacmed.v64n3.53015>.

Introduction

Syncope is a major syndromic complex which supposes great challenge for diagnosis and therapy to health personnel in charge of patient care. The importance of the initial study, and short and

medium term risk assessment, lies in the difference between the relatively benign causes represented by vasovagal episodes and potentially fatal causes in a short period of time, such as conditions secondary to cardiovascular disease (1).

The economic burden, both direct and indirect, is highly relevant; this cost is primarily represented by intra-hospital expenses generated by the decision to hospitalize a patient with syncope, decision often unnecessarily taken by fear or lack of knowledge from health personnel about the life-threatening event. A new study finds that in a university hospital, 100% of patients admitted to the emergency room due to syncope were hospitalized (2); however, if early and medium term risk identification tools are used, lower costs can be achieved through outpatient management (3).

Literature shows that multiple works have been developed on risk stratification scores, most of them obtained from the emergency department for short-term prognosis. Some of them, like the San Francisco Syncope Rule (SFSR), the Boston Syncope Rule, Oesil, Steps and Egsys, have shown deficiencies mainly when attempting external validation, exposing different results (4,5). This study evaluated the ROSE risk score diagnostic performance in a cohort of patients admitted for syncope to the emergency room.

Materials and methods

All patients older than 18, who attended the emergency rooms of Fundación Hospital San Carlos and Fundación Santafé de Bogotá due to syncope, between August 2013 and February 2014, were included. Syncope is defined as a transient altered state of consciousness and postural tone with spontaneous recovery without neurological deficit (except for amnesia after the event).

We excluded patients with loss or alteration of consciousness that was not secondary to transient cerebral hypoperfusion (consumption of alcohol or hypoglycemia), with head trauma presented before the syncopal episode, with a known history of epilepsy—typical seizure episode or prolonged postictal seen or described by witnesses—and persistent neurological deficit suggestive of acute vascular brain attack or transient cerebral ischemia.

The study was approved by the ethics and research committees of the two institutions involved and patients signed an informed consent to participate. Follow-up was conducted through the review of medical records, if the patient was hospitalized during the follow-up period or by telephone, if the patient had been discharged. A descriptive analysis of demographic characteristics, data specific to the syncopal event, history, physical examination and paraclinical exams requested at admission was made.

The following were considered as adverse outcomes: death, acute myocardial infarction, need for percutaneous or surgical coronary revascularization, severe aortic stenosis, aortic dissection, cardiac tamponade, pulmonary embolism, dilated cardiomyopathy with a left ventricular rejection fraction of <35%, diagnosis of major bradyarrhythmias and electrotherapy—pacemaker implant, pauses longer than three seconds, 2:1 AV Block, Type II Mobitz AV block, complete AV block, bradycardia under 30 bpm, alternating bundle branch block, pacemaker malfunction related to capture fault—, diagnosis of tachyarrhythmia—ventricular or sustained supraventricular tachyarrhythmia—, defibrillator implant, cardiac resynchronization therapy device implant, malfunction of cardioverter-defibrillator or cardiac resynchronization therapy device due to inadequate treatment of sustained ventricular arrhythmias, significant bleeding—need for transfusions, endoscopy requiring endoscopic treatment due to bleeding or need for surgical intervention due to bleeding—, lesions after the syncopal event that

could affect life—head trauma, spinal fracture or long bones—and emergency readmission.

The description of all the variables that make up the ROSE score was made for each patient: abnormality of electrocardiogram (presence of pathological Q waves, except for Lead III), presence or absence of anemia ($HB \leq 9$ g/dl), bradycardia (heart frequency ≤ 50 lpm), abnormal rectal examination when gastrointestinal bleeding was suspected, chest pain with syncope, abnormal brain natriuretic peptide (BNP) (≥ 300 pg/ml) and oxygen saturation abnormal to the environment ($<94\%$).

All causes and major cardiovascular adverse events were considered as primary outcomes, while events such as mortality and independent major adverse events were considered as secondary outcomes.

A univariate analysis was conducted according to the nature of the variables: qualitative variables are presented with absolute numbers and proportions, while quantitative variables are presented with measures of central tendency (average) and statistical dispersion (standard deviation). A Kolmogorov–Smirnov test was performed to define the statistical tests that would be used for bivariate analysis and whether quantitative variables followed a normal distribution. For the prediction of the primary outcome at 7 and 30 days, the operating characteristics of the test were evaluated, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Data were analyzed through the SPSS V19 program.

Results

During the August 2013 - February 2014 period, 60 patients were selected. The average age was 66.47 ± 20.3 and 56.7% ($n=34$) of the population were females. Demographic characteristics are shown in Table 1.

Table 1. Demographic characteristics of the study population.

Characteristic		n (%)
Age (\bar{x} , σ)		66.4 (20.3)
Female		34 (56.7)
Race	Mestizo	51 (85.0)
	Caucasian	7 (11.7)
	Indigenous	2 (3.3)
Weight (\bar{x} , σ)		60.4 (10.2)
Size (\bar{x} , σ)		1.6 (0.08)
BMI		24.7 (3.7)

\bar{x} : average; σ : standard deviation; BMI: body mass index.

Source: Own elaboration based on the data obtained in the study.

In this population, 31.7% ($n=19$) had previous syncopal events; of these, 42% ($n=8$) registered a single syncopal event in the last six months, 15.8% ($n=3$) two episodes and 36.9% ($n=7$) three or more episodes. Other frequent antecedents were previous heart disease (25%) and heart failure diagnosis (21.7%) (Table 2).

The characteristics of the syncope episode commonly showed prodromal symptoms (51.7%) and dyspnea (36.7%). The average time elapsed between the time of syncope and consultation to the emergency department was three hours ($RIQ=1.87-16.25$). The average hospital stay for the study of syncope and management of complications was 8.9 days (0.5 to 60) (Table 3).

Table 2. Medical history of the study population.

Medical history	n (%)
Previous diagnosis of heart disease	15 (25.0)
Ischemic cardiopathology	9 (15.0)
Valvular heart disease	3 (5.0)
Dilated cardiomyopathy	5 (8.3)
Congenital heart disease	1 (1.7)
Diagnosis or clinical evidence of heart failure	13 (21.7)
Diagnosis or clinical evidence of peripheral arterial disease	5 (8.3)
Diagnosis or clinical evidence of chronic kidney disease	9 (15.0)
Previous diagnosis of stroke	3 (5.0)
Arrhythmias	4 (6.7)
Pacemaker	1 (1.7)
Implantable cardioverter defibrillator	1 (1.7)

Source: Own elaboration based on the data obtained in the study.

Table 3. Characteristics of the syncope episode of the study population.

Syncope characteristics	n (%)
Dyspnea	22 (36.7)
Dehydration	1 (1.7)
Gastrointestinal bleeding	1 (1.7)
Chest pain	25 (41.7)
Syncope during exertion	1 (1.7)
Syncope in supine position	7 (11.7)
Syncope with high temperature	3 (5.0)
Post-trauma unconsciousness	17 (28.3)
Prodromal symptoms	31 (51.7)
Palpitations	8 (13.3)
Blurry vision	16 (26.7)
Diaphoresis	19 (31.7)
Nausea	17 (28.3)
Piloerection	7 (11.7)

Source: Own elaboration based on the data obtained in the study.

The physical exam at admission found mainly: systolic blood pressure of 125.1 ± 23.3 mmHg, diastolic blood pressure of 72.5 ± 13.7 mmHg, heart rate of 68.5 ± 17.7 bpm, respiratory rate of 19.6 ± 9.5 rpm and oxygen saturation of $90.05 \pm 12.4\%$. Electrocardiogram at admission found alterations in 76.7% (n=46).

The main abnormal electrocardiographic findings were: non-specific changes in ST-T (54.3%), axis deviation (34.8%), sinus bradycardia (32.6%), left ventricular hypertrophy (30%), intraventricular conduction block (26%) and atrioventricular block (15%). 10.9% of patients had a pre-excitation pattern; the corrected mean of the QT interval was 412ms (normal). Within laboratory data taken on admission to the emergency unit, the obtained values of the variables that are part of the ROSE risk score were taken into account. 40% of the study population (n=24) showed values greater than or equal to BNP 300 pg/ml (abnormal) with a median of 524.5 pg/ml (225.75-1727). Regarding hemoglobin, the average was 13.7 g/dl.

The incidence of the outcome at 7 and 30 days of follow up was 40% (n=24) and 8.3% (n=8), respectively (Table 4). 80% (n=40) of patients had a high risk score at admission, and 31.2% of them had an adverse outcome. All patients with a composite outcome between at 7 and 30 days already had such outcome before 7 days had passed. The association evaluated with a Pearson's chi-squared test was 1.522 with $p=0.217$.

Table 4. Outcomes at 7 and 30 days of follow-up.

Outcomes	7 days n (%)	30 days n (%)
Death	-	2 (3.3)
AMI	8 (13.3)	3 (5.0)
Arrhythmias	10 (16.7)	2 (3.3)
FV	3 (5.0)	4 (6.7)
TV	2 (3.3)	2 (3.3)
Ventricular pause	1 (1.7)	-
Ventricular pause	3 (5.0)	-
Asystole	3 (5.0)	-
Pulmonary embolism	-	1 (1.7)
Stroke	1 (1.7)	-
Intracranial hemorrhage	1 (1.7)	-
Significant bleeding	3 (5.0)	-
Transfusion	3 (5.0)	-
Re-admission	-	1 (1.7)
Sepsis	1 (1.7)	-
CPR	-	2 (3.3)
Percutaneous coronary intervention	4 (6.7)	-
Pacemaker	5 (8.3)	2 (3.3)
CDI	2 (3.3)	2 (3.3)
Surgery of abdominal aortic aneurysm	-	1 (1.7)
Coronary artery bypass graft	-	1 (1.7)
Another cardiac surgery	-	1 (1.7)
Vasopressor	4 (6.7)	1 (1.7)
Antiarrhythmic	6 (10.0)	3 (5.0)
ICU	19 (31.7)	1 (1.7)
Ischemia	10 (16.7)	2 (3.3)
Bradycardia	6 (10.0)	-
Sinus pauses	1 (1.7)	-
Mobitz II	1 (1.7)	-
Third degree AV block	2 (3.3)	-
Paroxysmal (SVT)	4 (6.7)	-
TV	2 (3.3)	1 (1.7)

Source: Own elaboration based on the data obtained in the study.

Within components of ROSE risk score, 2 (3.3%) had fecal occult blood, 2 (3.3%) anemia ($Hb \leq 9$ g/dl), 24 chest pain (40%), 7 (11.7%) Q waves in EGG, 24 (40.7%) BNP > 300 pg/mL, 15 (25%) bradycardia (< 50 bpm), and 39 (65%) $SaO_2 < 94\%$.

There was no loss of follow-up at 7 or 30 days. For prediction of primary outcome —major, serious and death—, the ROSE risk score showed sensitivity, specificity, PPV and NPV of 60%,

18.18%, 6.25% and 83.33% respectively. The area under the ROC curve was 0.62 (95%CI: 0.45 to 0.78) (Figure 1 and 2).




Figure 1. Curve of operating characteristic of the receiver of the ROSE scale for composite outcome at 7 days. Source: Own elaboration based on the data obtained in the study.




Figure 2. Curve of operating characteristic of the receiver of the ROSE scale for composite outcome at 30 days. Source: Own elaboration based on the data obtained in the study.

Discussion

The main finding of this study is that the ROSE risk score did not have adequate performance for prognosis in this Colombian cohort to find sensitivity, specificity, and low VPP for mortality and major events.

When comparing populations with syncope in this study with those of the original study by Reed *et al.* (6), it is possible to see that, in both, the average age was 65 and that patients had a higher

prevalence of cardiovascular comorbidities and similar risks of greater complications. A striking difference found in this research is a lower prevalence of previous history of syncopal episodes compared to the original study (32% vs. 43%).

Previous history of syncope could represent more unidentified or previously unstudied cardiovascular comorbidity; however, as there are people with recurrent or frequent syncope, the neurally mediated mechanism or reflection is the most associated with these episodes and generates better prognosis and lower incidence of ominous events. In addition, patients present with higher prevalence of heart failure (21.7% vs. 5.1%) and high risk of sudden death; this important difference may explain the high prevalence (68%) of high BNP (>300 pg/ml) and why this population is sicker from a cardiovascular standpoint; however this is against adequate ROSE sensitivity rule.

The history of coronary artery disease —previous myocardial infarction— was also higher (15% vs. 10%), although it was not significant. In the original study, the cause of syncope was identified in the emergency department in 44% of cases, compared to what was found here, where most patients were hospitalized mainly due to uncertain diagnosis and short term prognosis.

76% of patients in this study had an abnormal electrocardiogram (ECG) on admission, ranging from subtle abnormalities to signs of significant structural heart disease; in contrast, the study of Reed *et al.* (6) found that 96% of patients had an ECG in sinus rhythm with no major abnormalities on admission.

The follow-up after one year of the cohort of patients who underwent the ROSE score allowed finding that 52% of the events were manifested after the first 30 days of evaluation. Sensitivity decreased while specificity increased (71.6% and 71.1%, respectively), which is a typical behavior of a diagnostic test with greater statistical power (7) and which leads to infer that the scale loses performance as the index event progresses.

It is important to assess the need for external validations since other scores found lower prognosis yield. Thus, e.g., Saccilotto *et al.* (8) conducted a systematic review that assessed 12 studies that used the San Francisco scale; in this study, the sensitivity and specificity of the scale varied considerably in relation to the original derivation —sensitivity of 87% and specificity of 52% in the systematic review, and sensitivity of 96% and specificity of 62% in the derivation—. Similarly, the external validation of this scale showed distant values (sensitivity 89% and specificity 69%). As a consequence, it can be said there are specific factors of the population that make risk scales have a different behavior (9,10).

The high negative predictive value of the ROSE scale (83%) must be emphasized, which would make this score a useful tool in low-risk patients. All patients experiencing an outcome until day 7 had no new events at 30 days, which reflects the need to broaden the sample of patients with syncope.

Prior to using BNP as a variable of cardiovascular adverse outcome with a risk score as ROSE, its usefulness as an independent risk factor in patients with syncope had already been evaluated. In the study of Reed *et al.* (11) the value of BNP for predicting adverse outcomes at three months in adult patients with syncope events was evaluated, finding that a value of 100 lpg/ml was more sensitive than that found in institutional risk prediction guides at three months of follow-up with similar specificity. It is likely that BNP is not useful for predicting outcomes in low risk groups, although no assessment of the issue is found. In this same study, more than 40% of patients had a BNP value greater than or equal to 300 pg/mL, representing a large sample of high risk patients for post-syncopal cardiovascular complications.

D'Ascenzo *et al.* (12) evaluated 43 315 patients with syncope and determined that 10.4% had underlying cardiac abnormalities, being bradyarrhythmia the most common (4.8%); this is far exceeded in this study, where bradyarrhythmia was the third most frequent electrocardiographic finding (32.6%), preceded by axis deviation and changes in ST segment and T wave.

An important limitation when considering the use of a serum marker for damage or myocardial overload, as in the case of BNP in the assessment of the prognosis of patients with syncope, is based on the fact that BNP itself could be identified only in older patients, with higher prevalence of structural heart disease and heart failure, diseases that imply a worse prognosis and increased incidence of cardiovascular complications. However, this measurement represents a more objective marker of heart disease or cardiac involvement from another source compared to a medical history and, a much more subjective, physical examination.

Regarding the general limitations of the study, the most important is sample size, followed by the high variability reported in the reading of the electrocardiogram, which may vary depending on the observer's experience. This makes a reliable standardized reading of these studies necessary, since the detection of electrocardiographic abnormalities allows the identification of patients with cardiogenic syncope, the main etiology associated with increased morbidity and mortality. Similarly, the follow-up time (30 days) can be considered minimal, because it limits the detection of long-term events.

Conclusions

Given the low calculated sensitivity and the small sample of patients, the ROSE risk score does not have a good diagnostic performance as a predictor of major cardiovascular outcomes and death at 30 days in the study population. Nevertheless, all patients with a low risk score (0) could be assessed on an outpatient basis given the high NPV.

The authors of this document express that its content derives from a research project (degree project) conducted by the Department of Internal Medicine from Universidad Nacional de Colombia and authored by Manuel Agustín Paz Meneses (13).

Conflict of interests

None stated by the authors.

Funding

None stated by the authors.

Acknowledgements

To Fundación Hospital San Carlos for providing the patients required for the study.

References

1. **Guiada F, Silvestri I, Rossillo A, Nicotera PG, Manzillo GF, Raviele A.** Psychiatric profile, quality of life and risk of syncopal recurrence in patients with tilt-induced vasovagal syncope. *Europace*. 2005;7(5):465-71. <http://doi.org/c7jsnf>.
2. **Méndez A, Rojas IT, Amarís O, Mora G.** Rendimiento pronóstico de reglas de decisión clínica en síncope. *Acta Med. Colomb*. 2015;40(1):36-44.
3. **Blanc JJ, Benditt DG.** Syncope: definition, classification, and multiple potential causes. In: Benditt DG, Blanc JJ, Brignole M, Sutton RS, editors. The evaluation and treatment of syncope. A Handbook for clinical practice. Elmsford: Futura Blackwell; 2003. p. 3-10.
4. **Costantino G, Perego F, Dipaola F, Borella M, Galli A, Cantoni G, et al.** Short- and long-term prognosis of syncope, risk factors, and role of hospital admission: results from the StePS (Short-Term Prognosis of Syncope) study. *J. Am. Coll. Cardiol*. 2008;51(3):276-83. <http://doi.org/d734d7>.
5. **Del Rosso A, Ungar A, Maggi R, Giada F, Petix NR, De Santo T, et al.** Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general hospital: the EGSYS score. *Heart*. 2008;94(12):1620-6. <http://doi.org/cg4ff4>.
6. **Reed MJ, Newby DE, Coill AJ, Prescott RJ, Jacques KG, Gray AJ.** The ROSE (risk stratification of syncope in the emergency department) study. *J. Am. Coll. Cardiol*. 2010;55(8):713-21. <http://doi.org/dggq69>.
7. **Reed MJ, Henderson SS, Newby DE, Gray AJ.** One-year prognosis after syncope and the failure of the ROSE decision instrument to predict one-year adverse events. *Ann. Emerg. Med*. 2011;58(3):250-6. <http://doi.org/bmw87b>.
8. **Sacciloto RT, Nickel CH, Bucher HC, Steyerberg EW, Bingisser R, Koller MT.** San Francisco syncope rule to predict short term serious outcomes: a systematic review. *CMAJ*. 2011;183(15):1116-26. <http://doi.org/bgcx65>.
9. **Sun BC, Mangione CM, Merchant G, Weiss T, Shlamovitz GZ, Zargaraff G, et al.** External validation of the San Francisco Syncope Rule. *Ann. Emerg. Med*. 2007;49(4):420-7. <http://doi.org/bp8mhq>.
10. **Quinn JV, Stiell IG, McDermott DA, Sellers KL, Kohn MA, Wells GA, et al.** Derivation of the San Francisco Syncope Rule to predict patients with short-term serious outcomes. *Ann. Emerg. Med*. 2004;43(2):224-32. <http://doi.org/cnkn73>.
11. **Reed MJ, Newby DE, Coill AJ, Jacques KG, Prescott RJ, Gray AJ.** Role of brain natriuretic peptide (BNP) in risk stratification of adult syncope. *Emerg. Med. J*. 2007;24(11):769-73. <http://doi.org/fnpq2x>.
12. **D'Ascenzo F, Biondi-Zoccai G, Reed MJ, Gabayan GZ, Suzuki M, Costantino G, et al.** Incidence, etiology and predictors of adverse outcomes in 43,315 patients presenting to the emergency department with syncope: an international meta-analysis. *Int. J. Cardiol*. 2013;167(1):57-62. <http://doi.org/fxnpps>.
13. **Paz-Meneses MA.** Aplicación del puntaje de riesgo en síncope "Rose", para predicción de mortalidad y desenlaces cardiovasculares mayores, a 7 y 30 días, en pacientes adultos. [Tesis]. Bogotá, D.C.: Universidad Nacional de Colombia; 2014.